CYTOMEDIX AUTOLOGEL™ CLINICAL
TRIAL PRESENTATION RECEIVES TOP AWARD AT APMA ANNUAL MEETING
ROCKVILLE, Md., Aug 23, 2006 – Cytomedix, Inc. (AMEX: GTF),
today announced that a presentation based on the clinical trial for
the AutoloGel™ System, received the “Outstanding Oral Abstract
Presentation” award at the American Podiatric Medical Association
Annual Scientific Meeting that was held August 7 though 10 in Las
Vegas, NV.
The award-winning presentation was based on the abstract “A
Prospective, Randomized, Controlled, Blinded, Multicenter Pivotal
Trial of a Platelet-Rich Plasma Gel Versus Control When Added to the
Standard of Care in the Treatment of Non-Healing Diabetic Foot
Ulcers,” and was delivered by Vickie R. Driver, DPM, MS, Director of
Clinical Research at the Center for Lower Extremity Ambulatory
Research (CLEAR) at the Dr. William M Scholl College of Podiatric
Medicine at Rosalind Franklin University of Medicine and Science in
North Chicago, and Chief of the National Center for Limb
Preservation at Advocate Lutheran General Hospital in Park Ridge
Illinois. Dr. Driver was an investigator in the AutoloGel™ clinical
trial. This data was also published recently in the peer-reviewed
journal, Ostomy/Wound Management.
Dr. Driver commented, “I am honored and pleased to receive such a
distinguished award from my colleagues at APMA. It is with sincere
gratitude that I congratulate Cytomedix for developing this new
novel therapy to help treat diabetic foot ulcers. When these new
therapies are developed, it is, without question, vital that we
spend the money and conduct clinical research trials to better
understand how patients will benefit. We need to continue to support
biomedical companies that support pivotal research to help us heal
diabetic foot wounds and thereby prevent or reduce amputations.”
“We are extremely pleased that this presentation by Dr. Driver
should receive such a prestigious award at the annual meeting of the
country’s leading podiatric medical professionals,” stated Chairman
and Chief Executive Officer Kshitij Mohan. “This is further evidence
that the medical profession has begun to see the merits of the
AutoloGel™ System for use on chronic foot ulcers in people with
diabetes. Cytomedix congratulates Dr. Driver for her outstanding
performance and is honored and grateful for her research on the
AutoloGel™ System.”
The APMA Annual Meeting was attended by approximately 4,000 medical
lower extremity specialists who witnessed hundreds of presentations
and speeches in the course of the four-day Annual Scientific
Meeting.
ABOUT THE AMERICAN PODIATRIC MEDICAL ASSOCIATION
The American Podiatric Medical Association is the premier
professional organization representing the nation's Doctors of
Podiatric Medicine (podiatrists). The APMA represents approximately
80 percent of the podiatrists in the country. Within APMA's umbrella
of organizations are 53 component societies in states and other
jurisdictions, as well as 21 affiliated and related societies.
APMA's Council on Podiatric Medical Education is the body designated
by the US Department of Education to accredit the nation's podiatric
medical schools. In addition, the Council has the responsibility to
approve residency programs and continuing medical education
programs. The Council recognizes certifying boards within podiatric
medicine which meet its standards.
ABOUT CYTOMEDIX
Cytomedix, Inc. is a biotechnology company specializing in processes
and products derived from autologous platelet releasates for uses
with wounds and other applications. The current offering is
AutoloGel™System, a process that utilizes an autologous platelet gel
composed of multiple growth factors, other platelet releasates, and
fibrin matrix. The Company has announced favorable results from its
blinded, prospective, multi-center clinical trial on the use of its
technology with diabetic foot ulcers. Additional information
regarding Cytomedix is available at: http://www.cytomedix.com
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to
historical facts are forward-looking statements that are intended to
fall within the safe harbor rule for such statements under the
Private Securities Litigation Reform Act of 1995. The information
contained in the forward-looking statements is inherently uncertain,
and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict
or control, including among others, the success of new sales
initiatives, governmental regulation, acceptance by the medical
community and competition. There is no guarantee that the FDA will
complete its review of the Company’s 510(k) submission for a
specific wound healing indication within any estimated timeframe, or
that the FDA will fully agree with the Company in the interpretation
of the data or the regulatory pathway and provide marketing
clearance. Further, even assuming the FDA grants the Company’s
request for marketing clearance, there is no guarantee that the
Company will receive Medicare reimbursement for its product; the
Company’s marketing efforts will be successful; or that it will be
able to achieve its other strategic goals.
There is no guarantee that the information reported by Dr. Driver in
the presentation discussed above is accurate or that further review
of Dr. Driver’s’ conclusions or testing of AutoloGel ™ will prove
such information to be accurate. There is also no guarantee that the
Company’s current capitalization will be sufficient to attain its
goals or that future funding will be available to the Company on
acceptable terms. These forward-looking statements are subject to
known and unknown risks and uncertainties that could cause actual
events to differ from the forward-looking statements. More
information about some of these risks and uncertainties may be found
in the reports filed with the Securities and Exchange Commission by
Cytomedix, Inc. Except as is expressly required by the federal
securities laws, Cytomedix undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, changed circumstances or future events or for any other
reason.
SOURCE: Cytomedix, Inc.
The Wall Street Group, Inc.
Ron Stabiner
(212) 888-4848 |
